BLPH - Bellerophon Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Bellerophon Therapeutics, Inc.

184 Liberty Corner Road
Suite 302
Warren, NJ 07059
United States
908-574-4770
http://www.bellerophon.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees17

Key Executives

NameTitlePayExercisedYear Born
Mr. Fabian TenenbaumCEO & Director657.12kN/A1974
Mr. Assaf KornerCFO & Sec.381.67kN/A1978
Mr. Peter FernandesChief Regulatory & Safety Officer467.79kN/A1955
Ms. Amy EdmondsVP of Clinical Operations & Admin.N/AN/A1972
Mr. Hunter GilliesActing Chief Medical OfficerN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its products include INOpulse, a proprietary pulsatile nitric oxide delivery system for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase IIB clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; that has completed Phase IIa clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that is in Phase II dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.

Corporate Governance

Bellerophon Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.